Business
Shoppers Drug Mart Corporation Prices Issuance Of An Aggregate Of $500 Million Principal Amount Of Series 3 And Series 4 Medium Term Notes
/NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE SERVICES/ TORONTO, Jan. 14 ...
About this update from Serrano Resources Ltd.
[{"type":"text","content":"\n\n\n\n/NOT FOR DISTRIBUTION IN THE UNITED STATES OR OVER UNITED STATES WIRE\nSERVICES/\n\n\nTORONTO, Jan. 14 /CNW/ - Shoppers Drug Mart Corporation (TSX: SC) today\nannounced that it has priced the issuance of $250 million aggregate principal\namount of 4.80% unsecured medium term notes, Series 3, due January 20, 2012\nfor aggregate net proceeds of $249,312,500, as well as the issuance of $250\nmillion aggregate principal amount of 5.19% unsecured medium term notes,\nSeries 4, due January 20, 2014 for aggregate net proceeds of $249,082,500. The\nnotes will be offered pursuant to pricing supplements to the Company's short\nform base shelf prospectus dated May 22, 2008. The pricing supplements will be\nfiled with the securities regulatory authorities in each of the provinces of\nCanada. RBC Dominion Securities Inc., Scotia Capital Inc., CIBC World Markets\nInc., TD Securities Inc., BMO Nesbitt Burns Inc., National Bank Financial Inc.\nand Merrill Lynch Canada Inc. are acting as agents with respect to these\nofferings. The issuance of these notes is expected to close on or about\nJanuary 20, 2009 and the proceeds will be used to refinance existing\nindebtedness, including repayment of all amounts outstanding under the\nCompany's 364 day senior unsecured credit facility. As a result of using the\nproceeds to refinance existing indebtedness, the consolidated debt position of\nthe Company is expected to remain substantially unchanged.\n\n\nThese offerings are only being made by way of prospectus. The pricing\nsupplements and the short form base shelf prospectus, including the documents\nincorporated by reference therein, contain important information concerning\nthese securities. Prospective investors should read the pricing supplements\nand the short form base shelf prospectus before making an investment decision.\n\n\nThis news release does not constitute an offer to sell or the\nsolicitation of an offer to buy the securities in any jurisdiction. The\nsecurities being offered have not been approved or disapproved by any\nregulatory authority nor has any such authority passed upon the accuracy or\nadequacy of the pricing supplements or the short form base shelf prospectus.\n\n\nThe securities referred to herein have not been and will not be\nregistered under the United States Securities Act of 1933, as amended, or any\nstate securi...